Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Archives
Print | Email | Share | Comments (0)

Israeli Biotech Company Takes Novel Approach to Diabetic Ulcer Treatment


Jun 19, 2012

An Israeli biotech company's cell therapy, designed to treat hard-to-heal diabetic ulcers, is now in phase 3 testing in the United States.

The company, Macrocure, reports that its product, CureXcell, demonstrated impressive success rates at Israel's largest HMO. The Israeli trial, called a "Real Life" phase 4 trial, was conducted with 131 subjects at seven clinics operated by Clalit Health Service.

Macrocure announced the trial results recently in Atlanta at the Symposium on Advanced Wound Care. The company reported that after 24 weeks, its therapy achieved a 68 percent closure rate for diabetic foot ulcers and an 81 percent closure rate for venous ulcers. The closure rate for all ulcers was 71 percent.

Diabetic foot ulcers occur in about 15 percent of all patients who have diabetes. The wounds are a great concern because they can become infected and lead to gangrene and the need for amputation.

CureXcell uses activated white blood cells obtained from healthy young adult donor blood. The activated cells are injected directly into non-healing wounds, where they release an array of active allogeneic immune cells. These cells release necessary cytokines and growth factors that allow wounds to heal.

The product has been used to treat about 5,000 patients with various types and severities of hard-to-heal wounds in Israel. While CureXcell has received the go-ahead to be marketed in Israel, it is not yet licensed for sale in either the United States or Canada. 


Categories: Amputation, Blood, Diabetes, Diabetes Health, Diabetic, Foot Ulcer, Research



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.